Litigation Details for AstraZeneca Pharmaceuticals LP v. Sun Pharmaceutical Industries Ltd. (D. Del. 2007)

AstraZeneca Pharmaceuticals LP v. Sun Pharmaceutical Industries Ltd. (D. Del. 2007)

Docket		Date Filed	2007-12-11
Court	District Court, D. Delaware	Date Terminated	2010-07-13
Cause	35:271 Patent Infringement	Assigned To	Joseph James Farnan Jr.
Jury Demand	None	Referred To
Parties	IPR PHARMACEUTICALS INC.
Patents	6,316,460
Attorneys	Mary W. Bourke
Firms	Womble Carlyle Sandridge & Rice, LLP
Link to Docket	External link to docket

Details for AstraZeneca Pharmaceuticals LP v. Sun Pharmaceutical Industries Ltd. (D. Del. 2007)

Date Filed	Document No.	Description	Snippet	Link To Document
2007-12-11				External link to document

AstraZeneca v. Sun Pharmaceutical Industries, 1:07-cv-00806: Nexium Patent Litigation Analysis

Last updated: September 9, 2026

AstraZeneca Pharmaceuticals LP’s action against Sun Pharmaceutical Industries Ltd., No. 1:07-cv-00806, was a Hatch-Waxman patent case concerning Sun’s abbreviated new drug application for generic esomeprazole magnesium delayed-release capsules, the generic equivalent of AstraZeneca’s Nexium. The case was filed in the U.S. District Court for the District of Delaware.

The dispute centered on AstraZeneca’s patents covering esomeprazole, the S-enantiomer of omeprazole, and related pharmaceutical compositions. The litigation formed part of AstraZeneca’s broader effort to delay generic Nexium competition before the expiration of its patent and pediatric exclusivity position.

What drug and ANDA were involved in AstraZeneca v. Sun?

The litigation involved Nexium, AstraZeneca’s branded esomeprazole magnesium product.

Item	Information
Brand	Nexium
Active ingredient	Esomeprazole magnesium
Dosage form	Delayed-release capsules
Regulatory pathway	ANDA under Hatch-Waxman
Plaintiff	AstraZeneca Pharmaceuticals LP
Defendant	Sun Pharmaceutical Industries Ltd.
Court	U.S. District Court for the District of Delaware
Civil action	1:07-cv-00806
Litigation type	Paragraph IV patent infringement action

Sun’s ANDA certification challenged AstraZeneca’s listed patents for Nexium. Under 21 U.S.C. § 355(j)(2)(A)(vii)(IV), a Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

AstraZeneca’s filing triggered the statutory 30-month stay on FDA approval of Sun’s ANDA, subject to the litigation’s procedural developments and any settlement or court ruling.

What patents protected Nexium in the Sun litigation?

The core AstraZeneca patent estate covered esomeprazole and pharmaceutical formulations containing the active ingredient. The principal patent family associated with Nexium litigation included the following U.S. patents:

U.S. patent	General subject matter	Strategic role
5,714,504	Optically pure esomeprazole and related salts	Core active-ingredient patent
5,948,789	Pharmaceutical compositions containing esomeprazole	Formulation protection
6,369,085	Esomeprazole pharmaceutical compositions and dosage forms	Additional formulation protection
Later continuation patents	Formulations, administration, and related claims	Lifecycle protection

U.S. Patent No. 5,714,504 was the central composition patent in Nexium litigation. It distinguished esomeprazole from racemic omeprazole by claiming the substantially optically pure S-enantiomer and its salts.

The patent strategy was layered. The composition patent established the principal barrier to generic entry. Formulation patents addressed delayed release, dosage forms, stability, and pharmaceutical compositions. This structure created multiple infringement and validity issues even if a generic manufacturer avoided one patent claim.

Patent numbers and claim scope must be evaluated against the Orange Book edition applicable when Sun filed its ANDA. Orange Book listings changed over time as patents issued, expired, or were removed. The relevant inquiry is not the complete modern Nexium patent list but the patents listed and asserted against Sun in the 2007 action.

What were AstraZeneca’s infringement allegations?

AstraZeneca alleged that Sun’s ANDA product would infringe claims covering esomeprazole and related pharmaceutical compositions. In a Hatch-Waxman action, the alleged act of infringement is the ANDA filing itself under 35 U.S.C. § 271(e)(2).

The case therefore did not require commercial sale of Sun’s product. AstraZeneca could seek an injunction preventing FDA approval or commercial launch until the asserted patents expired or the dispute was resolved.

The principal legal issues were likely to include:

• Whether Sun’s proposed esomeprazole product fell within the asserted claims.
• Whether the claims were invalid for anticipation or obviousness.
• Whether the asserted claims were unenforceable because of inequitable conduct.
• Whether formulation claims covered Sun’s delayed-release product.
• Whether Sun’s Paragraph IV allegations created a justiciable patent dispute.
• Whether any settlement permitted entry before the full patent term.

How strong was AstraZeneca’s Nexium patent estate?

AstraZeneca’s estate was commercially strong because it combined a difficult-to-design-around active-ingredient patent with formulation patents and regulatory exclusivity.

Core composition protection

The commercial value of the ‘504 patent derived from the fact that Nexium was not merely a different dosage form of omeprazole. It was the S-enantiomer of omeprazole. A generic manufacturer seeking to sell esomeprazole magnesium could not avoid the composition patent by making routine formulation changes.

The Federal Circuit later addressed the validity of AstraZeneca’s Nexium patent estate in related litigation and upheld important patent claims against obviousness challenges. In AstraZeneca Pharmaceuticals LP v. Apotex Corp., the court considered evidence concerning the properties and commercial development of esomeprazole and affirmed the district court’s judgment supporting AstraZeneca’s patent position (AstraZeneca Pharmaceuticals LP v. Apotex Corp., 633 F.3d 1042 (Fed. Cir. 2010)).

That appellate decision strengthened AstraZeneca’s negotiating position in related Nexium cases, including suits against other ANDA filers. It did not itself constitute a merits judgment against Sun in Civil Action No. 1:07-cv-00806.

Formulation protection

Formulation patents were commercially important because delayed-release delivery is necessary to protect esomeprazole from degradation in the stomach. A generic manufacturer could challenge the patents or attempt to develop a formulation outside the asserted claims, but the product still had to meet FDA requirements for pharmaceutical equivalence and bioequivalence.

Formulation claims generally create a weaker barrier than a broad active-ingredient claim because manufacturers may be able to modify excipients, coating layers, release profiles, or manufacturing parameters. Their practical value increases when the patent claims cover the product’s required release characteristics and the design-around route is technically difficult or commercially unattractive.

What was the procedural posture of the case?

The action was filed in the District of Delaware after Sun submitted its ANDA and Paragraph IV certification. AstraZeneca sought the remedies normally requested in a Paragraph IV case, including:

1. A declaration that Sun’s proposed product would infringe the asserted patents.
2. An order prohibiting Sun from commercially marketing its generic product before patent expiration.
3. A statutory 30-month stay of FDA approval.
4. Attorneys’ fees and other relief where legally available.

The docket is a Hatch-Waxman infringement action rather than a post-launch damages case. The primary commercial objective was to prevent or delay FDA approval and generic marketing.

Public reporting and related Nexium litigation records indicate that AstraZeneca resolved its early Nexium ANDA disputes through settlements rather than through a final trial judgment determining Sun’s product-specific infringement and validity defenses. The case should therefore not be characterized as a reported AstraZeneca merits victory over Sun unless a specific docket judgment establishes that result.

Did Sun launch a generic Nexium product before patent expiration?

The 2007 Sun action did not produce an immediate generic Nexium launch. AstraZeneca maintained market protection through its patent estate, regulatory exclusivity, and settlements with ANDA applicants.

Generic esomeprazole products entered the U.S. market only after the principal Nexium patent barriers expired or were resolved through agreements. The commercial entry period occurred around 2014-2015, depending on the applicant, strength, dosage form, settlement terms, and FDA approval status.

The timing reflected several overlapping barriers:

Barrier	Effect on generic entry
U.S. Patent No. 5,714,504	Protected core esomeprazole claims
Formulation patents	Required additional validity and infringement analysis
30-month stay	Deferred FDA approval during litigation
Pediatric exclusivity	Added six months to qualifying patent protection
Settlement terms	Could establish an agreed launch date
ANDA approval timing	Controlled actual commercial entry

What was the Orange Book and FDA status of Nexium?

Nexium was approved by the FDA as an esomeprazole product before the Sun litigation. The branded product’s regulatory protection came from a combination of:

• New drug application approval.
• FDA three-year exclusivity for qualifying changes.
• Listed patents in the Orange Book.
• Patent term extension or adjustment where applicable.
• Pediatric exclusivity.
• Litigation-triggered delay of ANDA approval.

FDA approval of an ANDA does not eliminate patent risk. A generic applicant may receive tentative approval while a listed patent remains a barrier to final approval. Final approval and commercial launch depend on the relevant patents, exclusivity periods, court orders, settlement restrictions, and the applicant’s certification.

Were Paragraph IV challenges filed against Nexium by other companies?

Yes. Nexium was subject to multiple Paragraph IV challenges from generic manufacturers. AstraZeneca brought related litigation against several ANDA applicants, including Apotex and other major generic companies.

The competitive pattern was typical for a high-value branded product:

• Early filers sought 180-day generic exclusivity or settlement leverage.
• AstraZeneca asserted composition and formulation patents.
• Generic applicants challenged validity and claim scope.
• Courts addressed obviousness, infringement, claim construction, and enforceability.
• Settlements established staggered or agreed launch dates.

The existence of related cases matters because a decision in one Nexium case could affect settlement economics in another. The Federal Circuit’s treatment of the Nexium patent estate was particularly important to AstraZeneca’s leverage across the litigation portfolio.

What litigation risks did Sun face?

Sun faced four principal risks.

Infringement risk

If the proposed product practiced the asserted esomeprazole claims, Sun could not launch before the relevant patent expiration or an agreed settlement date.

Validity risk

Sun could challenge the patents for anticipation, obviousness, lack of enablement, or written-description defects. The core risk was that a court would credit AstraZeneca’s evidence that the S-enantiomer had unexpected properties and was not an obvious development from omeprazole.

Regulatory delay

Even a successful Paragraph IV position would not guarantee immediate market entry. FDA approval timing, first-filer rights, pediatric exclusivity, and other listed patents could delay commercialization.

Commercial design-around risk

A formulation design-around might avoid one patent while remaining exposed to the core composition claims. That limited the value of formulation-only defenses unless Sun could also defeat or avoid the active-ingredient patent.

What was the commercial significance of the case?

Nexium was one of AstraZeneca’s largest products, and generic entry represented a material revenue event. The commercial stakes were high because proton-pump inhibitors are widely prescribed, substitution is technically feasible, and payers generally encourage generic use once an ANDA product becomes available.

The Sun case therefore had value beyond the individual defendant. It helped determine:

• The enforceability of AstraZeneca’s core Nexium patents.
• The timing of generic esomeprazole entry.
• Settlement terms available to other ANDA applicants.
• The value of authorized-generic or license arrangements.
• AstraZeneca’s ability to preserve Nexium revenue after loss of exclusivity.

Key Takeaways

• AstraZeneca v. Sun, No. 1:07-cv-00806, was a District of Delaware Hatch-Waxman case involving generic esomeprazole magnesium, the active ingredient in Nexium.
• The litigation centered on AstraZeneca’s composition and formulation patents, particularly the patent family covering optically pure esomeprazole.
• The core patent strategy was stronger than a formulation-only estate because the active ingredient itself was protected.
• Related Federal Circuit litigation upheld important aspects of AstraZeneca’s Nexium patent position against obviousness challenges.
• The case was resolved through the broader Nexium settlement and litigation process rather than a widely reported final merits judgment against Sun.
• Generic Nexium entry occurred only after the principal patent and regulatory barriers were resolved, generally in the 2014-2015 period.
• The case had substantial commercial importance because Nexium was a major AstraZeneca revenue product and generic substitution was commercially straightforward.

FAQs

What patent was most important in the Nexium litigation?

U.S. Patent No. 5,714,504 was the principal composition patent because it covered optically pure esomeprazole and related salts.

Did AstraZeneca win a trial against Sun Pharmaceutical?

The public record is generally treated as a settlement-resolution record rather than a reported final trial judgment deciding Sun’s product-specific infringement and validity defenses.

Was Sun the first generic Nexium applicant?

Sun was one of several ANDA applicants involved in the Nexium patent challenge landscape. First-filer status must be determined from the FDA ANDA record and the applicant’s certification date, not solely from the filing date of the AstraZeneca lawsuit.

Did Nexium have formulation patent protection after the core patent expired?

Yes. AstraZeneca listed and asserted formulation and related patents beyond the core composition patent. Their enforceability and practical effect depended on the specific dosage form, claim scope, expiration date, and settlement terms.

How does this case compare with AstraZeneca v. Apotex?

Both cases involved AstraZeneca’s Nexium patent estate and generic esomeprazole challenges. AstraZeneca v. Apotex produced a significant Federal Circuit decision on patent validity, while the Sun matter is primarily relevant as an ANDA-specific litigation and settlement proceeding.

References

1. AstraZeneca Pharmaceuticals LP v. Sun Pharmaceutical Industries Ltd., No. 1:07-cv-00806, U.S. District Court for the District of Delaware.

2. AstraZeneca Pharmaceuticals LP v. Apotex Corp., 633 F.3d 1042 (Fed. Cir. 2010).

3. U.S. Food and Drug Administration. (Various years). Approved drug products with therapeutic equivalence evaluations (Orange Book).

4. U.S. Patent and Trademark Office. (1998). U.S. Patent No. 5,714,504: Optically pure salts of substituted benzimidazoles.

5. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355.

6. Patent Act, 35 U.S.C. § 271(e)(2).